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Abstract 
Purpose: To study the dexamethasone/corticotrophin releasing hormones (DEX/CRH) in depressed 
and healthy patients and to analyse the occurrence of relapse connected to hormonal dysregulation. 
Methods: A total of 117 depressive patients between 20 and 70 years of age were included in the study 
group and 40 healthy patients between 25 and 60 years of age in the control group. Group I consisted 
of 59 patients who received sertraline 50 - 100 mg/day for 5 weeks along with a low dose of 30 mg T3. 
Group II included 58 patients who received dexamethasone 1 mg orally for 5 weeks. DEX/CRH levels 
were analyzed. Adrenocorticotrophic hormone and cortisol levels in the blood were analysed by 
immuno-radiometric assay. Cortisol levels were also analysed by kinetic assay method. 
Results: In group I, among the 59 patients that received sertraline 50-100 mg/day for 5 weeks with a 
low dose of 30 mg T3, relapse was observed in 12 (20.3 %) of them. The area under the curve (AUC) 
was 13.9 ± 6.4 ng.min.1000/mL, which was higher than that for healthy individuals (3.8 ± 3.6 
ng.min.1000/mL). Group I patients with relapse showed an adrenocorticotrophic hormone AUC of 16.9 ± 
2.4 ng.min.1000/mL, while group II patients exhibited AUC of 13.9 ± 6.4 ng.min.1000/mL.  
Conclusion: The results emphasizes the need to test hormonal responses to different types of 
antidepressants. 
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Depression is a severe psychiatric disorder 
involving multiple etiological factors such as the 
surrounding environment and genetics [1]. The 
main precipitating factor in depression is stress, 
which can be treated with antidepressants [2-5]. 
Many researchers have reported clear evidence 
of altered endocrine factors and dysregulation of 
metabolism due to mood disorders [6]. 
 
There is no single marker that is linked to depre- 
ssive disorders. Many studies have reported a 
link between hormonal abnormalities and 
depressive disorders, and the combination of 
dexamethasone/corticotrophin releasing 
hormones (DEX/CRH) is a known indicator of 
hypothalamic, pituitary, and adrenal system 
function [7]. Previous studies have shown a link 
between the hypothalamic-pituitary-thyroid 
hormonal axis and depression. Low levels of 
thyroid stimulating hormone (TSH) are observed 
in patients with depression [8,9]. Most studies 
have focused on developing a test to determine 
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the function of the hypothalamic-pituitary-thyroid-
adrenocorticol system because it plays an 
essential role in regulating corticotrophin 
releasing hormone, which impacts patients with 
depression. Based on these results, 
antidepressant therapeutics have been 
developed to overcome this disorder among 
depressed patients [10]. 
 
Depressive patients’ urine and plasma have high 
levels of free cortisol [11]. It seems that 
depression leads to the release of increased 
levels of corticotropin-releasing hormone in 
cerebrospinal fluid [12] and reduced levels of 
adrenocorticotrophic hormone after 
administration of antidepressants. Our study was 
designed to determine the responses to the use 
of antidepressants. We used a highly sensitive 
test to detect altered hypothalamic-pituitary-
thyroid-adrenocorticol hormone regulation. We 
also focused on evaluating stress paradigms, 
such as cold pressor and mental arithmetic, and 
their effect on DEX/CRH levels in depressed and 
healthy patients with stress due to other reasons, 
such as illness or disorder. We also analysed the 







The study was carried out in Department of 
Psychiatry, The Medical Services Section and 
The Seventh People's Hospital of Hangzhou, 
Zhejiang Province, China, during the period of 
March 2015 to March 2017. The Institutional 
Ethical Board of The Seventh People's Hospital 
of Hangzhou, Zhejiang Province, China approved 
the study with ref number SPHH 144-14/15. The 
study was conducted after obtaining the informed 




A total of 117 patients between 20 to 70 years of 
age were included in the study.40 control group 
patients in the age of 25 to 60 years of age who 
are with stress due to illness and disorders were 
included in the study. The study group patients 
were categorised based on the structural clinical 
interview for DSM - IV Axis I Disorder [13]. For 
most of the patients, Hamilton Rating Scale of 
depression score was between 16 and 17 before 




The inclusion criteria were hospitalised patients, 
age > 20 years, and both male and female 
gender, while the exclusion criteria were patients 
< 20 years, patients on drug or alcohol, and 
pregnant women.  
 
All the patients, both in the study group and the 
control group, were divided into 2 groups. Group 
I consisted of 59 patients who received sertraline 
50 mg/day. They were given Sertraline for 5 
weeks to assess the improvement in patient’s 
condition. If the patients did not respond the 
dosage were increased to 100 mg / day. Group I 
patients were also given low dose of 30 mg of 
T3. The prognosis of the patients was assessed 
based on the Hamilton Rating Scale for 
Depression (HRSD) score. Reduction of more 
than 50 % was taken as good prognosis. All the 
59 patients were followed for 5 weeks to 18 
months to observe for any relapse and 
improvement in the depression state. Twenty 
control group patients were assessed by cold 
pressor test and mental arithmetic calculation for 
a fixed time. 
 
Group II included 58 patients who received 
Dexamethasone 1 mg orally. They were 
assessed for 5 weeks to observe the prognosis 
of patient’s mental health condition. DEX / CRH 
test were done. Global Assessment finding were 
done at end of every 2nd week. No hormone was 
given before starting the therapy in group II 
patients. Patients who had relapse were also 
followed up with factors taken into consideration 
such as time taken for relapse, duration of 
relapse and dosage of treatment in the patients 
were assessed.  
 
All the assessments were done by trained 
Psychiatrist. The scale of rating depressed 
followed in our study was the Hamilton Anxiety 
Rating Scale [13]. 
 
Parameters for analysis of stress 
 
These parameters were measured to analyse 40 
healthy control group patients (20 in group I and 




Cooling water was used. The patients were 
asked to soak their feet in cool water for 3 min 
and asked to keep out for 2 min which was 




Random numbers projected on the slide were 
shown to the healthy individuals with illness and 
disorders. They have to calculate the number 
randomly by adding, subtracting, multiplying and 
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dividing. A time limit of 15 s was given to 
complete the task. The task was repeated for 5 
times with 10 s interval for 10 min. 
 
Thyroid-releasing hormone test 
 
Patients in both groups were kept in fasting on 
the day of blood collection after 1.5 weeks of 
treatment. Blood samples were collected to 
assess the TSH level. After which 0.75 mg of 
TRH was given IV route and blood were 
collected at 30 min, 1 and 1.5 h time intervals to 
assess the level of TSH in blood. Maximum TSH 
value was determined. 
 
Hormonal assessment test 
 
One milligram of dexamethasone was given 
orally. DEX/CRH test was done on the same day 
of assessing TSH levels. Blood samples were 
collected at the interval of 30 min, 1 and 1.5 h to 
assess the ACTH and Cortisol levels in blood. 
After blood collection CRH 75 µg were given by 
IV route. Again blood samples were collected at 
30 min, 45 min, 1 h and 1.5 h interval. A total of 8 
mL blood was collected to measure ACTH (pmol 
/ L) and cortisol levels (nmol / L) in the blood. 
ACTH levels were analysed by Immuno-
radiometric assay. Cortisol Level were also 
analysed by Kinetic assay method. All the 
parameters and test were analysed with respect 




Statistical analysis was done by Fischer’s exact 
test and Mann-Whitney U tests using SPSS 
software version 21.0. T-test was calculated to 
determine the hormonal test data against age 
and sex of the patients. Correlation coefficient of 
association was analysed based on the 
Recurrence and responding nature of the 





Out of 117 patients included in our study, 62 
(52.9 %) were female and 55 (47.1 %) were 
male; all of the patients were 20 – 70 years old, 
with a mean age of 42.8 ± 4.5 years. All of the 
demographic details, such as age, gender, family 
history, relapse, duration of hospital stay, prior 
treatment received, and dose of antidepressant 
taken, were obtained from hospital records. Of 
the 40 healthy control group patients, 25 (62.5 
%) were male and 15 (37.5 %) were female. The 
control group patients were 25 – 60 years of age, 
with a mean age of 52.1 ± 3.8 years. There were 
no differences based on age, but female patients 
required longer stays than male patients in both 
the study group and in the control group. A 
significant difference was observed in the 
number of relapses and in hormonal responses 
between the groups. Differences were 
considered statistically significant when p > 
0.001 (present study, p = 0.013; Table 1). 
 
Table 1: Demographic profile of the patients 
 
Parameter Group I Group II Control 
Age 
(years) 


















history of  
Relapse 







20 weeks   










22.1±4.1 22.4±5.3 17.1±3.3 
Treatment 
received 













59 - - 
 
Among the 59 group I patients with depression, 
39 (66.1 %) were female and 20 (33.9 %) were 
male. These patients were 40–65 years of age, 
with a mean age of 44.9 ± 5.6 years. Among the 
control group patients, 12 (60 %) were female 
and 8 (40 %) were male; the age rage was 35–
58 years, with a mean age of 46.5 ± 6.7 years. 
Of the group I patients who received sertraline 
50-100 mg/day for 5 weeks followed by 18 
months of a low dose of 30 mg T3, only 12 
showed relapse (20.3 %). A total of 23 (38.9 %) 
patients showed relapse within 18 months of the 
study. All of the 59 group I patients strictly 
adhered to the medication regime. Only two of 
the patients had poor compliance, which we 
resolved by giving instructions to the patient’s 
family members. Tension and anxiety were 
assessed in 20 healthy patients performing tasks 
such as the cold pressor and mental arithmetic 
calculations. We recorded the time required to 
complete the tasks and found significant 
differences (p = 0.011). When Task I and Task II 
were compared, the score was significantly 
reduced between time intervals. The change in 
score was observed when patients were given 
time to relax between tasks. This change was 
significant (p < 0.01). The hormone levels in both  
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Table 2: DEX/CRH test between relapse and non-relapse patients 
 
Parameter Relapse No relapse 
Group I Group II Group I Group II 
DEX cortisol level before treatment with 
dexamethasone 
34.8±26.9 36.5±18.9 44.7±42.3 43.7±41.8 
ACTH level (ng/L) 16.9±2.4 13.9±6.4 11.5±3.8 12.7±4.3 
Cortisol level (nmol/L) 298 ± 161.4 268 ± 124.9 214.4 ± 140.2 210.8±137.3 
Elevated level (n) 12 18 47 40 
AUC value mg  h/L 24.1±22.8 23.4±20.9 3.8±3.6 4.8±2.9 
 
the study and the control groups were elevated 
between 30 min and 1 h (Table 2). 
 
Group II included 58 patients; 23 (39.6 %) were 
female and 35 (60.3 %) were male. The mean 
age was 47.2 ± 4.2 years. Among the 20 control 
group patients, 7 (35 %) were female and 13 (65 
%) were male, with a mean age of 39.6 ± 2.4 
years. The study group patients received 1 mg 
dexamethasone orally for 5 weeks. In both the 
study and control groups, female patients with 
Hamilton Rating Scale for Depression (HAM–D) 
scores of 17 were hospitalized longer than male 
patients with the same scores. 
 
The cortisol response among the group II 
patients who received dexamethasone 1 mg was 
increased compared with that among the group I 
patients who received sertraline with T3. The 
area under the time-course curve (AUC) was 
13.9 ± 6.4 ng × min × 1000 / ml, which was 
higher than the AUC for healthy individuals, 
which was only 3.8 ± 3.6 ng × min × 1000 / ml  (p 
< 0.01). 
 
Multiple logistic regression analysis with the AUC 
of the cortisol response as the dependent 
variable and age and severity of depression as 
independent variables revealed statistical 
significance (p < 0.01). The patients in both 
group I and group II who did not have relapse 
continued the treatment for 18 months; however, 
18 (13.8 %) patients in group II had relapse. 
 
After treatment to correct ACTH and cortisol 
levels, DEX/CRH levels were measured in the 
relapse patients and non-relapse patients. The 
ACTH and cortisol levels were found to be high 
in group I patients who had relapse, with an AUC 
of 16.9 ± 2.4 ng × min × 1000 / mL; whereas in 
group II, the AUC was less at 13.9 ± 6.4 ng × min 
× 1000 / mL, because the group II patients 
received 1 mg dexamethasone before starting 
therapy. The risk of relapse was 3.98 (95 % CI: 
0.85–2.63). In the group 1 patients who did not 
have relapse, the cortisol level was 214.4 ± 
140.2 nmol/L, whereas the cortisol level was 298 
± 161.4 nmol/L in the patients who had relapse. 
The cortisol level was found to be the most 
important factor for the DEX/CRH test response. 
There was a significant difference between the 
relapse patients and the non-relapse patients (p 




Our study compared the results of the DEX/CRH 
and TRH tests in patients with depression in both 
group I and group II. Out of 117 patients, only 41 
patients showed relapse within 2 years of 
discharge. Our study showed that the age and 
body mass index of the patients had no effect on 
the ACTH/CRH or TSH levels with respect to 
hypothalamic-pituitary-adrenal or hypothalamic-
pituitary-thyroid changes in depressed persons. 
Our study results are consistent with those of 
other studies, which previously reported no 
changes in hormonal responses to the DEX/CRH 
test with respect to age [14].  Heuser et al and 
Kudielka et al [15,16] reported significant 
hormonal changes with age, but those studies 
were performed with healthy individuals. In our 
study, we did not see any changes in DEX/CRH 
and TRH levels because relapse might not be 
associated with age factors. 
 
We found significant differences in hormonal 
changes to the DEX/CRH and TRH levels 
between male and female patients. Female 
patients were hospitalized for longer periods than 
males. Our study is similar to those by Kunugi et 
al, Kunzel et al, and Heuser et al [14,17,18], who 
reported similar differences in hormonal 
responses to the DEX/CRH test. Our study 
showed that the TRH response in patients with 
smaller AUC values was mainly in female 
patients rather than in male patients. A previous 
study by Kunzel et al [14] reported peak 
hormonal changes in women rather than in men 
when the TRH test was performed, which agrees 
with the female preponderance observed in our 
study. 
 
Our study showed significant changes in the 
AUCs of ACTH and cortisol depending on the 
antidepressant used for treatment, although the 
HAM-D and GAF scores remained the same. 
Previous studies by Rybakowski and 
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Twardowska et al [19] showed no changes in the 
DEX/CRH test with the hypothalamic-pituitary-
adrenal axis in depressive patients, which is 
consistent with our results. 
 
Carpenter et al reported that DEX/CRH tests with 
elevated cortisol levels should not be used as 
biomarkers to identify depression. In our study, 
relapse and DEX/CRH levels were significantly 
correlated. Relapse patients showed varied 
ACTH AUC levels compared with non-relapse 
patients, which is in agreement with study a by 
Hatzinger et al [20] of the correlation between 
DEX/CRH and recurrence of depression. 
 
Many researchers have reported that 
supplementing T3 before treatment was effective 
in controlling depression. Our study also 
supports the administration of T3 before therapy 
because, in some patients, depression occurs 
because of TRH deficiency, which can be 
avoided with T3 supplementation [21]. 
 
Limitations of the study 
 
This study was limited to a small patient 
population. We studied only patients with general 
depression and did not categorize the patients 
based on particular depressive conditions. 
Further research to find markers to detect 
relapse is needed with larger sample sizes and 
more focus on different depressive conditions. 
Only two antidepressants were tested in our 
study. Further studies are required to assess the 





The findings of this study emphasizes the need 
to test hormonal responses to different types of 
antidepressants. Further studies using different 
antidepressants are required to ascertain the 
action of antidepressants on hormonal 
responses. There is also the need for similar 
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